Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03592472 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT03592472 · ClinicalTrials.gov record · last posted 2025-04-13

A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)

StatusRecruiting
PhasePhase 3
Started2018-07-17
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This is a randomized, Phase 3, double-blind, placebo-controlled study of pazopanib plus abexinostat versus pazopanib plus placebo in patients with locally advanced unresectable or metastatic renal cell carcinoma (RCC).

Amendment record 19 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 19 times since 2018-07-09; most recent amendment 2025-04-09. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2021-05-10
Status change Active, Not Recruiting→Recruitingv16
2019-07-08
Status change Recruiting→Active, Not Recruitingv14
2018-08-06
Status change Not Yet Recruiting→Recruitingv3
Trial Details
NCT Number NCT03592472
Lead Sponsor Xynomic Pharmaceuticals, Inc.
Conditions Renal Cell Carcinoma
Enrollment 413 participants
Start Date 2018-07-17
Primary Completion 2026-12-30 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-04-13